HALO - Halozyme Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

8.193B

Cash

463.5M

Avg Qtr Burn

N/A

Short % of Float

6.92%

Insider Ownership

1.11%

Institutional Own.

99.50%

Qtr Updated

03/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
TLANDO Details TRT (Testosterone Replacement Therapy)	Approved Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Hylenex (hyaluronidase human injection) Details Drug absorption	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
DARZALEX (daratumumab) Details MM (Multiple myeloma)	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Xyosted (testosterone enanthate) Details Testosterone replacement	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Otrexup (Methotrexate) Details RA (rheumatoid arthritis) and psoriasis	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
DARZALEX FASPRO (Daratumumab and Hyaluronidase-fihj) Details AL (Light Chain) Amyloidosis	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tecentriq® SC w/ ENHANZE Details Solid tumor/s, Cancer	PDUFA Approval decision	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Selatogrel (P2Y12 receptor antagonist) Details Acute myocardial infarction	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
OCREVUS® (ocrelizumab) w/ ENHANZE Details Multiple sclerosis	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.